Abilify (Aripiprazole) Medicine For Bipolar Disorder Is Allowed To Be Marketing
Abilify drug was generally approved in 2004 for treating schizophrenia disease and this medicine was supposed to be used in treating bipolar disorder. Indeed, on April 8, 2008, the European Commission allowed Abilify medication (Aripiprazole) to be marketed for patients with Bipolar I Disorder.
Such kind of disease as Bipolar I Disorder contains one or more Manic Episodes or Mixed Episodes that are characterized by a person’s abnormally, irritable, expansive and continuously elevated mood. Aripiprazole tablets are aimed to treat moderate to severe manic episodes and to prevent new manic episodes.
ABILIFY medicine for bipolar disorder was developed by two companies: Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company.
A healthcare company Otsuka Pharmaceutical Co., Ltd., is involved in the development, research, manufacturing and marketing of pharmaceutical products. This company was founded in 1964 and states that they create new products for better health worldwide.
Bristol-Myers Squibb Company has mission to extend and enhance human life and their purpose is developing biopharmaceutical and related health care products.
The European Committee for Medicinal Products for Human Use (CHMP) made up a positive opinion due to the data from eight clinical trials. The randomized studies that included over 2,400 people have demonstrated ABILIFY drug to be effective, safe and tolerable not only in the treatment of moderate to severe manic episodes but also in prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to Abilify 20 mg treatment.
